Literature DB >> 22348281

Cardiovascular risk.

Rupert A Payne1.   

Abstract

Cardiovascular disease is a major, growing, worldwide problem. It is important that individuals at risk of developing cardiovascular disease can be effectively identified and appropriately stratified according to risk. This review examines what we understand by the term risk, traditional and novel risk factors, clinical scoring systems, and the use of risk for informing prescribing decisions. Many different cardiovascular risk factors have been identified. Established, traditional factors such as ageing are powerful predictors of adverse outcome, and in the case of hypertension and dyslipidaemia are the major targets for therapeutic intervention. Numerous novel biomarkers have also been described, such as inflammatory and genetic markers. These have yet to be shown to be of value in improving risk prediction, but may represent potential therapeutic targets and facilitate more targeted use of existing therapies. Risk factors have been incorporated into several cardiovascular disease prediction algorithms, such as the Framingham equation, SCORE and QRISK. These have relatively poor predictive power, and uncertainties remain with regards to aspects such as choice of equation, different risk thresholds and the roles of relative risk, lifetime risk and reversible factors in identifying and treating at-risk individuals. Nonetheless, such scores provide objective and transparent means of quantifying risk and their integration into therapeutic guidelines enables equitable and cost-effective distribution of health service resources and improves the consistency and quality of clinical decision making.
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2012        PMID: 22348281      PMCID: PMC3477342          DOI: 10.1111/j.1365-2125.2012.04219.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  159 in total

1.  Presenting information on risks.

Authors:  J J Coleman
Journal:  J Clin Pharm Ther       Date:  2005-12       Impact factor: 2.512

2.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

Review 3.  Genetics of diabetes and its complications.

Authors:  Stephen S Rich
Journal:  J Am Soc Nephrol       Date:  2006-01-04       Impact factor: 10.121

4.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

5.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.

Authors:  John Danesh; Sarah Lewington; Simon G Thompson; Gordon D O Lowe; Rory Collins; J B Kostis; A C Wilson; A R Folsom; K Wu; M Benderly; U Goldbourt; J Willeit; S Kiechl; J W G Yarnell; P M Sweetnam; P C Elwood; M Cushman; B M Psaty; R P Tracy; A Tybjaerg-Hansen; F Haverkate; M P M de Maat; F G R Fowkes; A J Lee; F B Smith; V Salomaa; K Harald; R Rasi; E Vahtera; P Jousilahti; J Pekkanen; R D'Agostino; W B Kannel; P W F Wilson; G Tofler; C L Arocha-Piñango; A Rodriguez-Larralde; E Nagy; M Mijares; R Espinosa; E Rodriquez-Roa; E Ryder; M P Diez-Ewald; G Campos; V Fernandez; E Torres; R Marchioli; F Valagussa; A Rosengren; L Wilhelmsen; G Lappas; H Eriksson; P Cremer; D Nagel; J D Curb; B Rodriguez; K Yano; J T Salonen; K Nyyssönen; T-P Tuomainen; B Hedblad; P Lind; H Loewel; W Koenig; T W Meade; J A Cooper; B De Stavola; C Knottenbelt; G J Miller; J A Cooper; K A Bauer; R D Rosenberg; S Sato; A Kitamura; Y Naito; T Palosuo; P Ducimetiere; P Amouyel; D Arveiler; A E Evans; J Ferrieres; I Juhan-Vague; A Bingham; H Schulte; G Assmann; B Cantin; B Lamarche; J-P Després; G R Dagenais; H Tunstall-Pedoe; M Woodward; Y Ben-Shlomo; G Davey Smith; V Palmieri; J L Yeh; A Rudnicka; P Ridker; F Rodeghiero; A Tosetto; J Shepherd; I Ford; M Robertson; E Brunner; M Shipley; E J M Feskens; D Kromhout; A Dickinson; B Ireland; K Juzwishin; S Kaptoge; S Lewington; A Memon; N Sarwar; M Walker; J Wheeler; I White; A Wood
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

6.  Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study.

Authors:  Joëlle A Erkens; Martien M J Panneman; Olaf H Klungel; Guido van den Boom; Margaret F Prescott; Ron M C Herings
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-11       Impact factor: 2.890

Review 7.  CVD risk factors and ethnicity--a homogeneous relationship?

Authors:  Nita G Forouhi; Naveed Sattar
Journal:  Atheroscler Suppl       Date:  2006-02-24       Impact factor: 3.235

8.  Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level.

Authors:  Thomas A Gaziano; Krisela Steyn; David J Cohen; Milton C Weinstein; Lionel H Opie
Journal:  Circulation       Date:  2005-12-06       Impact factor: 29.690

Review 9.  Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies.

Authors:  Leslee J Shaw; C Noel Bairey Merz; Carl J Pepine; Steven E Reis; Vera Bittner; Sheryl F Kelsey; Marian Olson; B Delia Johnson; Sunil Mankad; Barry L Sharaf; William J Rogers; Timothy R Wessel; Christopher B Arant; Gerald M Pohost; Amir Lerman; Arshed A Quyyumi; George Sopko
Journal:  J Am Coll Cardiol       Date:  2006-02-07       Impact factor: 24.094

10.  Support of evidence-based guidelines for the annual physical examination: a survey of primary care providers.

Authors:  Allan V Prochazka; Kristy Lundahl; Wesley Pearson; Sylvia K Oboler; Robert J Anderson
Journal:  Arch Intern Med       Date:  2005-06-27
View more
  23 in total

1.  QRISK or Framingham?

Authors:  John Robson; Julia Hippisley-Cox; Carol Coupland
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 2.  Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women.

Authors:  Enrique F Schisterman; Sunni L Mumford; Lindsey A Sjaarda
Journal:  Epidemiol Rev       Date:  2013-09-15       Impact factor: 6.222

3.  Association between dehydroepiandrosterone levels and cardiovascular risk in public sector health workers in a Peruvian region.

Authors:  Ricardo J Rojas; Janett V Chávez-Sosa; Rosmery Gutierrez-Ajalcriña; Salomón Huancahuire-Vega
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-06-19

4.  Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review.

Authors:  Andrew C Don-Wauchope; Pasqualina L Santaguida; Robert McKelvie; Judy A Brown; Mark Oremus; Usman Ali; Amy Bustamam; Nazmul Sohel; Stephen A Hill; Ronald A Booth; Cynthia Balion; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

5.  Cardiovascular Health in St. Louis Bosnian-Americans.

Authors:  Maximillian T Bourdillon; Asad S Akhter; Dejan Vrtikapa; Amer Avdagic; Marc A McNeese; Richard Lee; Dawn S Hui
Journal:  J Immigr Minor Health       Date:  2018-10

6.  Differences in Pulmonary and Extra-Pulmonary Traits between Women and Men with Chronic Obstructive Pulmonary Disease.

Authors:  Sara Souto-Miranda; Alex J van 't Hul; Anouk W Vaes; Jeanine C Antons; Remco S Djamin; Daisy J A Janssen; Frits M E Franssen; Alda Marques; Martijn A Spruit
Journal:  J Clin Med       Date:  2022-06-26       Impact factor: 4.964

Review 7.  A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age.

Authors:  Miodrag Janić; Mojca Lunder; Mišo Šabovič
Journal:  Biomed Res Int       Date:  2015-03-03       Impact factor: 3.411

8.  A Global View of the Relationships between the Main Behavioural and Clinical Cardiovascular Risk Factors in the GAZEL Prospective Cohort.

Authors:  Pierre Meneton; Cédric Lemogne; Eléonore Herquelot; Sébastien Bonenfant; Martin G Larson; Ramachandran S Vasan; Joël Ménard; Marcel Goldberg; Marie Zins
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

9.  Information and Risk Modification Trial (INFORM): design of a randomised controlled trial of communicating different types of information about coronary heart disease risk, alongside lifestyle advice, to achieve change in health-related behaviour.

Authors:  Barbora Silarova; Joanne Lucas; Adam S Butterworth; Emanuele Di Angelantonio; Christine Girling; Kathryn Lawrence; Stuart Mackintosh; Carmel Moore; Rupert A Payne; Stephen J Sharp; Guy Shefer; Zoe Tolkien; Juliet Usher-Smith; Matthew Walker; John Danesh; Simon Griffin
Journal:  BMC Public Health       Date:  2015-09-07       Impact factor: 3.295

10.  Screening for suspected coronary heart disease in patients, using integrated serum biochemical indices.

Authors:  Lei Feng; Chunfang Zhang; Shiyan Nian; Yinglu Hao; Wenbo Xu; Xingfeng Zhang; Jun Zhang; Li Li
Journal:  J Epidemiol Community Health       Date:  2015-09-25       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.